MOMENTA PHARMACEUTICALS AND SANDOZ SIGN EXCLUSIVE COLLABORATION TO DEVELOP COMPLEX GENERICS AND FOLLOW-ON VERSIONS OF BIOTECHNOLOGY DRUGS

Momenta Pharmaceuticals, Inc.,a biotechnology company specializing in the characterization and engineering of complex drugs, announced an exclusive collaboration with Sandoz, the generics business of Novartis, to develop four follow-on and complex generic versions of previously approved recombinant biotechnology and complex drugs.
Biotech Intelligence